Welcome to LookChem.com Sign In|Join Free

CAS

  • or
2'-Deoxyguanosine 5'-monophosphate, commonly referred to as dGMP, is a vital nucleotide derivative that is integral to the synthesis of DNA and RNA. It is composed of a deoxyribose sugar, a phosphate group, and the guanine nucleobase. dGMP is indispensable for the replication and transmission of genetic information, acting as a fundamental building block for DNA synthesis and contributing to the stability and structure of the DNA molecule. Furthermore, it is implicated in a range of cellular processes, including energy transfer and signal transduction. dGMP also holds potential therapeutic applications in addressing genetic disorders and viral infections, and it is utilized as a research tool in the fields of molecular biology and biochemistry.

902-04-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 902-04-5 Structure
  • Basic information

    1. Product Name: 2'-DEOXYGUANOSINE 5'-MONOPHOSPHATE
    2. Synonyms: dGMP·H2;(6r)-2,6-dimethyloct-7-en-2-ol;D-GMP;5'-DEOXYGUANYLIC ACID;2'-DEOXYGUANOSINE 5'-MONOPHOSPHATE;2’-deoxyguanosine5’-phosphate;2'-deoxyguanosine 5'-monophosphate free acid;2'-deoxy-5'-guanylic acid
    3. CAS NO:902-04-5
    4. Molecular Formula: C10H14N5O7P
    5. Molecular Weight: 347.22
    6. EINECS: 212-988-2
    7. Product Categories: N/A
    8. Mol File: 902-04-5.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 844.2°Cat760mmHg
    3. Flash Point: 464.4°C
    4. Appearance: /
    5. Density: 2.32g/cm3
    6. Refractive Index: N/A
    7. Storage Temp.: −20°C
    8. Solubility: N/A
    9. PKA: 1.86±0.10(Predicted)
    10. CAS DataBase Reference: 2'-DEOXYGUANOSINE 5'-MONOPHOSPHATE(CAS DataBase Reference)
    11. NIST Chemistry Reference: 2'-DEOXYGUANOSINE 5'-MONOPHOSPHATE(902-04-5)
    12. EPA Substance Registry System: 2'-DEOXYGUANOSINE 5'-MONOPHOSPHATE(902-04-5)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany: 3
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 902-04-5(Hazardous Substances Data)

902-04-5 Usage

Uses

Used in Pharmaceutical Industry:
2'-Deoxyguanosine 5'-monophosphate is used as a therapeutic agent for the treatment of genetic disorders and viral infections. Its role in DNA synthesis and its interaction with cellular processes make it a candidate for developing treatments that target specific genetic conditions or inhibit viral replication.
Used in Research Applications:
In the field of molecular biology, 2'-Deoxyguanosine 5'-monophosphate is used as a research tool for studying DNA synthesis, replication mechanisms, and the role of nucleotides in genetic information transfer. It aids in understanding the fundamental processes of life and can be utilized in the development of new diagnostic and therapeutic strategies.
Used in Biochemical Research:
2'-Deoxyguanosine 5'-monophosphate is employed in biochemical research to explore its role in energy transfer and signal transduction, providing insights into the complex interactions within cellular systems and potentially leading to the discovery of new biochemical pathways and targets for intervention.

Check Digit Verification of cas no

The CAS Registry Mumber 902-04-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 9,0 and 2 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 902-04:
(5*9)+(4*0)+(3*2)+(2*0)+(1*4)=55
55 % 10 = 5
So 902-04-5 is a valid CAS Registry Number.

902-04-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name dGMP

1.2 Other means of identification

Product number -
Other names 2'-DEOXYGUANOSINE 5'

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:902-04-5 SDS

902-04-5Synthetic route

2'-Deoxyguanosine
961-07-9

2'-Deoxyguanosine

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
Stage #1: 2'-Deoxyguanosine With trichlorophosphate at 20℃; for 0.15h; Flow reactor; Green chemistry;
Stage #2: With water at 20℃; Temperature; Flow reactor; Green chemistry; chemoselective reaction;
74%
With high Km 5'-nucleotidase; 5'-inosine monophosphate; ATP In various solvents at 37℃; pH=6.5; Enzyme kinetics; Further Variations:; Reagents; Solvents;
With Tris-HCl buffer; recombinant human mitochondrial deoxyguanosine kinase; ATP In water; dimethyl sulfoxide at 37℃; pH=7.6; Enzyme kinetics;
With recombinant deoxyribonucleoside kinase AtdNK from Arabidopsis thaliana (ecotype Columbia); ATP In aq. buffer Kinetics; Concentration; Reagent/catalyst; Enzymatic reaction;
With drosophila melanogaster deoxyribonucleoside kinase; ATP; magnesium chloride In aq. buffer at 37℃; for 24h; pH=8; Enzymatic reaction;
phosphoric acid monophenyl ester
701-64-4

phosphoric acid monophenyl ester

2'-Deoxyguanosine
961-07-9

2'-Deoxyguanosine

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
mit Hilfe von Malzenzym;
O3'-acetyl-O5'-benzyloxyphosphinoyl-2'-deoxy-guanosine

O3'-acetyl-O5'-benzyloxyphosphinoyl-2'-deoxy-guanosine

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
ueber mehrere Stufen;
C71H97N27O50P8

C71H97N27O50P8

A

cytidine 5'-(dihydrogen phosphate)
1032-65-1

cytidine 5'-(dihydrogen phosphate)

B

Thymidine
4603-58-1

Thymidine

C

Phosphoric acid (2R,3S,5R)-5-(5-amino-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-phosphonooxymethyl-tetrahydro-furan-3-yl ester 2,3,5-trihydroxy-pentyl ester

Phosphoric acid (2R,3S,5R)-5-(5-amino-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-phosphonooxymethyl-tetrahydro-furan-3-yl ester 2,3,5-trihydroxy-pentyl ester

D

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With alkaline phosphatase; snake venom phosphodiesterase Further byproducts given;
4-Methoxy-benzoic acid (2R,3S,5R)-5-(2-isobutyrylamino-6-oxo-1,6-dihydro-purin-9-yl)-2-phosphonooxymethyl-tetrahydro-furan-3-yl ester

4-Methoxy-benzoic acid (2R,3S,5R)-5-(2-isobutyrylamino-6-oxo-1,6-dihydro-purin-9-yl)-2-phosphonooxymethyl-tetrahydro-furan-3-yl ester

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With pyridine; ammonium hydroxide at 50℃; for 12h;
deoxyguanosine 5'-monophosphate 2-methylimidazolide

deoxyguanosine 5'-monophosphate 2-methylimidazolide

N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
7365-45-9

N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid

A

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

B

2-[4-(2-{[(2R,3S,5R)-5-(2-Amino-6-oxo-1,6-dihydro-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethoxy]-hydroxy-phosphoryloxy}-ethyl)-piperazin-1-yl]-ethanesulfonic acid

2-[4-(2-{[(2R,3S,5R)-5-(2-Amino-6-oxo-1,6-dihydro-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethoxy]-hydroxy-phosphoryloxy}-ethyl)-piperazin-1-yl]-ethanesulfonic acid

C

C20H24N10O13P2(2-)

C20H24N10O13P2(2-)

D

C30H35N15O19P3(3-)

C30H35N15O19P3(3-)

Conditions
ConditionsYield
With sodium chloride; magnesium chloride; polycytidylate In water at 23℃; for 480h; pH=7.85; Kinetics; Product distribution; Further Variations:; Reagents; Condensation; dimerization; oligomerization; hydrolysis;
Phosphoric acid mono-[(2R,3S,5R)-5-(2-benzoylamino-6-oxo-1,6-dihydro-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl] ester

Phosphoric acid mono-[(2R,3S,5R)-5-(2-benzoylamino-6-oxo-1,6-dihydro-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl] ester

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With ammonium hydroxide In water at 65℃; for 6h; Hydrolysis;
2'-deoxyguanosine 5'-triphosphate
2564-35-4

2'-deoxyguanosine 5'-triphosphate

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With water; MutT Hydrolysis;
dGTP

dGTP

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With MutT pyrophosphohydrolase; magnesium chloride In various solvent(s) at 23℃; pH=7.5; Enzyme kinetics;
Succ-LCAA-GPG functionalized with 5'-O-DMTr-N2i-Bu-dG

Succ-LCAA-GPG functionalized with 5'-O-DMTr-N2i-Bu-dG

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
Multistep reaction;
Acetic acid (2R,3S,5R)-5-(2-benzoylamino-6-oxo-1,6-dihydro-purin-9-yl)-2-hydroxymethyl-tetrahydro-furan-3-yl ester

Acetic acid (2R,3S,5R)-5-(2-benzoylamino-6-oxo-1,6-dihydro-purin-9-yl)-2-hydroxymethyl-tetrahydro-furan-3-yl ester

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: TPS-TAZ / pyridine / 2 h / 25 °C
2: NH4OH / H2O / 1 h / 25 °C
3: NH4OH / H2O / 6 h / 65 °C
View Scheme
Phosphoric acid (2R,3S,5R)-5-(2-benzoylamino-6-oxo-1,6-dihydro-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl ester 2-{2-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-ethanesulfonyl}-ethyl ester

Phosphoric acid (2R,3S,5R)-5-(2-benzoylamino-6-oxo-1,6-dihydro-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl ester 2-{2-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-ethanesulfonyl}-ethyl ester

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: NH4OH / H2O / 1 h / 25 °C
2: NH4OH / H2O / 6 h / 65 °C
View Scheme
C40H51N14O23P3
1363821-26-4

C40H51N14O23P3

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With water; sodium hydroxide at 60℃;
C40H51N14O23P3
1364653-25-7

C40H51N14O23P3

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With water; sodium hydroxide at 60℃;
d(ATTG)

d(ATTG)

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: Cooling with ice; UV-irradiation
2: water; sodium hydroxide / 60 °C
View Scheme
5'-d(CAGCTPMeG), PMe = methylphosphonate link

5'-d(CAGCTPMeG), PMe = methylphosphonate link

A

5'-d(pTPMeG), PMe = methylphosphonate link

5'-d(pTPMeG), PMe = methylphosphonate link

B

cytidine 5'-(dihydrogen phosphate)
1032-65-1

cytidine 5'-(dihydrogen phosphate)

C

2'-deoxyadenosine-5'-monophosphoric acid
653-63-4

2'-deoxyadenosine-5'-monophosphoric acid

D

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

E

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With nuclease P1 from Penicillium citrinum at 37℃; for 0.0833333h; pH=5.4; Enzymatic reaction;
C40H52N14O26P4

C40H52N14O26P4

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With acetic acid; N,N`-dimethylethylenediamine at 90℃; for 6h; pH=7.4;
5'-GGTGGTGGTGGTTGTGGTGGTGGTGG-3'

5'-GGTGGTGGTGGTTGTGGTGGTGGTGG-3'

A

2-amino-1,9-dihydro-6H-purin-6-one
73-40-5

2-amino-1,9-dihydro-6H-purin-6-one

B

2'-Deoxyguanosine
961-07-9

2'-Deoxyguanosine

C

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With 10 percent fetal bovine serum In aq. phosphate buffer at 37℃; for 96h;
5'-CTGGGTTGGGTTGGGTTGGGA-3'

5'-CTGGGTTGGGTTGGGTTGGGA-3'

A

2-amino-1,9-dihydro-6H-purin-6-one
73-40-5

2-amino-1,9-dihydro-6H-purin-6-one

B

2'-Deoxyguanosine
961-07-9

2'-Deoxyguanosine

C

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With 10 percent fetal bovine serum In aq. phosphate buffer at 37℃; for 96h;
morpholine
110-91-8

morpholine

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Desoxyguanosin-5'-phosphoromorpholidat
65861-57-6

Desoxyguanosin-5'-phosphoromorpholidat

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In water; tert-butyl alcohol96%
With dicyclohexyl-carbodiimide In water; tert-butyl alcohol Reflux;90%
With dicyclohexyl-carbodiimide In water; tert-butyl alcohol
2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

crotonaldehyde
123-73-9

crotonaldehyde

phosphoric acid mono-[3-hydroxy-5-(8-hydroxy-6-methyl-9-oxo-5,7,8,9-tetrahydro-6H-1,3,4,5,8a-pentaaza-cyclopenta[b]naphthalen-3-yl)-tetrahydrofuran-2-ylmethyl] ester sodium salt

phosphoric acid mono-[3-hydroxy-5-(8-hydroxy-6-methyl-9-oxo-5,7,8,9-tetrahydro-6H-1,3,4,5,8a-pentaaza-cyclopenta[b]naphthalen-3-yl)-tetrahydrofuran-2-ylmethyl] ester sodium salt

Conditions
ConditionsYield
With phosphate buffer; L-arginine at 50℃; for 2h; pH=8.0;92%
propionaldehyde
123-38-6

propionaldehyde

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

C13H20N5O7P

C13H20N5O7P

Conditions
ConditionsYield
With sodium cyanoborohydride In water at 20℃; Sealed tube;85%
hexanal
66-25-1

hexanal

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

C16H26N5O7P

C16H26N5O7P

Conditions
ConditionsYield
With sodium cyanoborohydride In water at 20℃; Sealed tube;85%
acetaldehyde
75-07-0

acetaldehyde

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

N2-ethyl-2'-deoxyguanosine-5'-phosphate

N2-ethyl-2'-deoxyguanosine-5'-phosphate

Conditions
ConditionsYield
With sodium cyanoborohydride In methanol; water at 50℃; for 48h;76%
C12H27N*C10H16N5O13P3

C12H27N*C10H16N5O13P3

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

C20H28N10O19P4

C20H28N10O19P4

Conditions
ConditionsYield
Stage #1: 2'-deoxyguanosine 5'-monophosphate With 1,1'-carbonyldiimidazole In N,N-dimethyl-formamide at 20℃; for 1h;
Stage #2: C12H27N*C10H16N5O13P3 In N,N-dimethyl-formamide at 20℃;
62%
3,4,6-tri-O-acetyl-α-D-glucopyranose-1,2-(t-butylorthoacetat)
4715-05-3

3,4,6-tri-O-acetyl-α-D-glucopyranose-1,2-(t-butylorthoacetat)

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

2'-deoxyguanosine 5'-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl phosphoric acid)
81788-38-7

2'-deoxyguanosine 5'-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl phosphoric acid)

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 25℃; for 20h;9%
styrene oxide
96-09-3

styrene oxide

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

A

O6-(2-hydroxy-2-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

O6-(2-hydroxy-2-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

B

C18H22N5O8P

C18H22N5O8P

C

1-(2-hydroxy-1-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

1-(2-hydroxy-1-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

D

1-(2-hydroxy-2-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

1-(2-hydroxy-2-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

E

2'-deoxyguanosin-5'-yl (hydroxy)(phenyl)ethyl hydrogen phosphate

2'-deoxyguanosin-5'-yl (hydroxy)(phenyl)ethyl hydrogen phosphate

Conditions
ConditionsYield
With ammonia; ammonium bicarbonate In methanol; water at 37℃; for 20h; pH=10.5; Alkylation; Further byproducts given;A 0.7%
B 3.8%
C 0.7%
D 4%
E n/a
styrene oxide
96-09-3

styrene oxide

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

A

C18H22N5O8P

C18H22N5O8P

B

C18H22N5O8P

C18H22N5O8P

C

N2-(2-hydroxy-1-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

N2-(2-hydroxy-1-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

D

N2-(2-hydroxy-2-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

N2-(2-hydroxy-2-phenylethyl)-2'-deoxyguanosine 5'-monophosphate

Conditions
ConditionsYield
With ammonia; ammonium bicarbonate In methanol; water at 37℃; for 20h; pH=10.5; Alkylation; Further byproducts given;A 3.8%
B 1.7%
C 3.6%
D 0.6%
Dehydroretronecine
23107-12-2

Dehydroretronecine

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

5'-monophosphate of 7-(deoxyguanosin-N2-yl)dehydrosupinidine
103958-13-0

5'-monophosphate of 7-(deoxyguanosin-N2-yl)dehydrosupinidine

Conditions
ConditionsYield
With potassium carbonate at 60℃; for 6h; pH=7.4;0.9%
2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

dimethyl sulfate
77-78-1

dimethyl sulfate

2-amino-7-methyl-6-oxo-9-(O5-phosphono-β-D-erythro-2-deoxy-pentofuranosyl)-1,6-dihydro-purinium betaine
22164-18-7

2-amino-7-methyl-6-oxo-9-(O5-phosphono-β-D-erythro-2-deoxy-pentofuranosyl)-1,6-dihydro-purinium betaine

Conditions
ConditionsYield
in wss.Loesung vom pH 7.2;
2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

adenosine 5'-diphosphate
58-64-0

adenosine 5'-diphosphate

2'-deoxyguanosine 5'-triphosphate
2564-35-4

2'-deoxyguanosine 5'-triphosphate

Conditions
ConditionsYield
With acetic acid phosphoric acid-anhydride in Gegenwart von Enzympraeparaten von Escherichia coli;
2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

2'-deoxyguanosine 5'-triphosphate
2564-35-4

2'-deoxyguanosine 5'-triphosphate

Conditions
ConditionsYield
in Gegenwart von Extrakten aus Maeusetumor;
2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

A

5′-deoxyguanosine diphosphate
3493-09-2

5′-deoxyguanosine diphosphate

B

2'-deoxyguanosine 5'-triphosphate
2564-35-4

2'-deoxyguanosine 5'-triphosphate

Conditions
ConditionsYield
With pyridine; tributyl-amine; phosphoric acid; dicyclohexyl-carbodiimide
With phosphoric acid; ATP in Gegenwart von Leberextrakten;
With pyridine; phosphoric acid; di-p-tolylcarbodiimide
With pyridine; phosphoric acid; dicyclohexyl-carbodiimide
With pyridine; phosphoric acid; di-p-tolylcarbodiimide
trimethyl phosphite
512-56-1

trimethyl phosphite

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

A

7-methylguanine
578-76-7

7-methylguanine

B

deoxyguanosine 5'-(methyl hydrogen phosphate)

deoxyguanosine 5'-(methyl hydrogen phosphate)

C

7-methyldeoxyguanosine 5'-phosphate

7-methyldeoxyguanosine 5'-phosphate

D

7-methyldeoxyguanosine 5'-(methyl hydrogenphosphate)

7-methyldeoxyguanosine 5'-(methyl hydrogenphosphate)

Conditions
ConditionsYield
In water at 37℃; for 48h; pH=7;A 6 % Spectr.
B 10 % Spectr.
C 6 % Spectr.
D 2 % Spectr.
trimethyl phosphite
512-56-1

trimethyl phosphite

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

A

1-methyldeoxyguanosine 5'-phosphate

1-methyldeoxyguanosine 5'-phosphate

B

Phosphoric acid mono-{(2R,3S,5R)-5-[2-amino-5-(formyl-methyl-amino)-6-oxo-1,6-dihydro-pyrimidin-4-ylamino]-3-hydroxy-tetrahydro-furan-2-ylmethyl} ester

Phosphoric acid mono-{(2R,3S,5R)-5-[2-amino-5-(formyl-methyl-amino)-6-oxo-1,6-dihydro-pyrimidin-4-ylamino]-3-hydroxy-tetrahydro-furan-2-ylmethyl} ester

C

Phosphoric acid mono-{(2R,3S,5R)-5-[2-amino-5-(formyl-methyl-amino)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-ylamino]-3-hydroxy-tetrahydro-furan-2-ylmethyl} ester

Phosphoric acid mono-{(2R,3S,5R)-5-[2-amino-5-(formyl-methyl-amino)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-ylamino]-3-hydroxy-tetrahydro-furan-2-ylmethyl} ester

Conditions
ConditionsYield
In water at 37℃; for 48h; pH=10;A 51 % Spectr.
B 3 % Spectr.
C 11 % Spectr.
In water at 37℃; for 24h; pH=10;A 40 % Spectr.
B 7 % Spectr.
C n/a
C18H14O3
80433-81-4

C18H14O3

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

A

9-((2R,4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-2-((1S,2S,3R,4S)-2,3,4-trihydroxy-1,2,3,4-tetrahydro-benzo[a]anthracen-1-ylamino)-1,9-dihydro-purin-6-one

9-((2R,4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-2-((1S,2S,3R,4S)-2,3,4-trihydroxy-1,2,3,4-tetrahydro-benzo[a]anthracen-1-ylamino)-1,9-dihydro-purin-6-one

B

9-((2R,4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-2-((1R,2S,3R,4S)-2,3,4-trihydroxy-1,2,3,4-tetrahydro-benzo[a]anthracen-1-ylamino)-1,9-dihydro-purin-6-one

9-((2R,4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-2-((1R,2S,3R,4S)-2,3,4-trihydroxy-1,2,3,4-tetrahydro-benzo[a]anthracen-1-ylamino)-1,9-dihydro-purin-6-one

Conditions
ConditionsYield
1.) CH3CN, 37 deg C, 2.) alkaline phosphatase, 37 deg C; Multistep reaction;
trans-3,4-dihydroxy-anti-1,2-epoxy-1,2,3,4-tetrahydro-7,12-dimethylbenzanthracene
130856-45-0, 74340-90-2, 86941-58-4, 86941-59-5, 111001-45-7, 111001-46-8, 115225-74-6, 135821-93-1, 135911-40-9

trans-3,4-dihydroxy-anti-1,2-epoxy-1,2,3,4-tetrahydro-7,12-dimethylbenzanthracene

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Phosphoric acid mono-{(2R,3S,5R)-3-hydroxy-5-[6-oxo-2-(2,3,4-trihydroxy-7,12-dimethyl-1,2,3,4-tetrahydro-benzo[a]anthracen-1-ylamino)-1,6-dihydro-purin-9-yl]-tetrahydro-furan-2-ylmethyl} ester
133551-48-1, 133645-08-6, 133645-09-7, 133645-10-0

Phosphoric acid mono-{(2R,3S,5R)-3-hydroxy-5-[6-oxo-2-(2,3,4-trihydroxy-7,12-dimethyl-1,2,3,4-tetrahydro-benzo[a]anthracen-1-ylamino)-1,6-dihydro-purin-9-yl]-tetrahydro-furan-2-ylmethyl} ester

Conditions
ConditionsYield
With tris-HCl-buffer In tetrahydrofuran; diethyl ether; acetone at 37℃;
(+/-)-trans-3,4-Dihydroxy-anti-1,2-epoxy-7-methyl-1,2,3,4-tetrahydrobenzanthracene
133645-02-0

(+/-)-trans-3,4-Dihydroxy-anti-1,2-epoxy-7-methyl-1,2,3,4-tetrahydrobenzanthracene

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Phosphoric acid mono-{(2R,3S,5R)-3-hydroxy-5-[6-oxo-2-(2,3,4-trihydroxy-7-methyl-1,2,3,4-tetrahydro-benzo[a]anthracen-1-ylamino)-1,6-dihydro-purin-9-yl]-tetrahydro-furan-2-ylmethyl} ester
133551-46-9, 133645-03-1, 133645-07-5, 133646-13-6

Phosphoric acid mono-{(2R,3S,5R)-3-hydroxy-5-[6-oxo-2-(2,3,4-trihydroxy-7-methyl-1,2,3,4-tetrahydro-benzo[a]anthracen-1-ylamino)-1,6-dihydro-purin-9-yl]-tetrahydro-furan-2-ylmethyl} ester

Conditions
ConditionsYield
With tris-HCl-buffer In acetone at 37℃;
2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

2'-dC-5'-MP deprotonated radical cation

2'-dC-5'-MP deprotonated radical cation

A

cytidine 5'-(dihydrogen phosphate)
1032-65-1

cytidine 5'-(dihydrogen phosphate)

B

2'-dG-5'-MP deprotonated radical cation

2'-dG-5'-MP deprotonated radical cation

Conditions
ConditionsYield
at 20℃; Rate constant; pH = 1;
2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

C10H14N5O7P(1+)

C10H14N5O7P(1+)

Conditions
ConditionsYield
With sodium chloride In water at 20℃; Quantum yield; Irradiation;
2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

5',8'-cyclo-2',5'-dideoxyguanosine
85899-55-4

5',8'-cyclo-2',5'-dideoxyguanosine

Conditions
ConditionsYield
In water Irradiation;
NA-AAF
6098-44-8

NA-AAF

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

Phosphoric acid mono-((2R,3S,5R)-5-{8-[acetyl-(9H-fluoren-2-yl)-amino]-2-amino-6-oxo-1,6-dihydro-purin-9-yl}-3-hydroxy-tetrahydro-furan-2-ylmethyl) ester

Phosphoric acid mono-((2R,3S,5R)-5-{8-[acetyl-(9H-fluoren-2-yl)-amino]-2-amino-6-oxo-1,6-dihydro-purin-9-yl}-3-hydroxy-tetrahydro-furan-2-ylmethyl) ester

Conditions
ConditionsYield
In ethanol; water pH 6;
N-methyl pyridinium 2-carboxaldehyde iodide salt
3784-97-2

N-methyl pyridinium 2-carboxaldehyde iodide salt

2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

2-(Bis-{[(2R,3S,5R)-5-(2-amino-6-oxo-1,6-dihydro-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethoxy]-hydroxy-phosphoryloxy}-methyl)-1-methyl-pyridinium; iodide

2-(Bis-{[(2R,3S,5R)-5-(2-amino-6-oxo-1,6-dihydro-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethoxy]-hydroxy-phosphoryloxy}-methyl)-1-methyl-pyridinium; iodide

Conditions
ConditionsYield
With piperidine In dimethyl sulfoxide; N,N-dimethyl-formamide for 3h; Ambient temperature;
2'-deoxyguanosine 5'-monophosphate
902-04-5

2'-deoxyguanosine 5'-monophosphate

C21H28N2O4(2+)*2I(1-)

C21H28N2O4(2+)*2I(1-)

C61H80N22O30P4(2+)*2I(1-)

C61H80N22O30P4(2+)*2I(1-)

Conditions
ConditionsYield
With piperidine In dimethyl sulfoxide; N,N-dimethyl-formamide for 3h; Ambient temperature;

902-04-5Relevant articles and documents

Mechanistic studies of the inhibition of MutT dGTPase by the carcinogenic metal Ni(II)

Porter, Dale W.,Nelson, Victor C.,Fivash Jr., Matthew J.,Kasprzak, Kazimierz S.

, p. 1375 - 1381 (1996)

Promutagenic 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-exo-dG) levels are increased in DNA of animals exposed to carcinogenic metals, such as Ni(II). Besides being generated directly in genomic DNA, 8-oxo-dG may be incorporated there from 8-oxo-7, 8-dihydro-2'-deoxyguanosine 5'-triphosphate (8-oxo- dGTP), a product of oxidative damage to the nucleotide pool. The Escherichia coli dGTPase MutT, and analogous dGTPases in rats and humans, have been suggested as a defense against such incorporation because they hydrolyze 8- oxo-dGTP to 8-oxo-7, 8-dihydro-2'-deoxyguanosine 5'-monophosphate (8-oxo- dGMP). MutT and its mammalian counterparts are Mg(II)-dependent enzymes. Ni(II), in turn, is known to interact antagonistically with Mg(II) in biological systems. Thus, we hypothesized that Ni(II) might inhibit the activity of MutT. As an initial examination of this hypothesis, we conducted enzyme kinetic studies of MutT to determine the effect of Ni(II) on MutT activity and the mechanisms involved. As found, Ni(II) inhibited Mutt in a concentration-dependent manner when either dGTP or 8-oxo-dGTP was the nucleotide substrate. Ni(II) was determined to be an uncompetitive inhibitor of MutT with respect to Mg(II) when dGTP was the substrate, with apparent K(i) of 1.2 mM Ni(II), and a noncompetitive inhibitor with respect to Mg(II) when 8-oxo-dGTP was the substrate, with apparent K(i) of 0.9 mM Ni(II). Hence, the two metal cations did not compete with each other for binding at the Mutt active site. This makes it difficult to predict Ni(II) effects on 8- oxo-dGTPases of other species. However, based upon the amino acid sequences of human and rat MutT-like dGTPases, their capacity for Ni(II) binding should be greater than that of MutT. Whether this could lead to stronger inhibition of those enzymes by Ni(II), or not, remains to be investigated.

Kinetics of Template-Directed Pyrophosphate-Linked Dideoxyguanylate Synthesis as a Function of 2-MeImpdG and Poly(C) Concentration: Insights into the Mechanism

Kanavarioti, Anastassia,Gangopadhyay, Sumana

, p. 7957 - 7964 (1999)

Aqueous solutions of deoxyguanosine 5′-monophosphate 2-methylimidazolide, 2-MeImpdG, yield primarily deoxyguanosine 5′-monophosphate, 5′dGMP, and pyrophosphate-linked dideoxyguanylate, dG5′ppdG, abbreviated G2p (see Chart 1). The initial rate of G2p formation, d[G2p]/dt in M h-1, determined at 23°C, pH 7.8, 1.0 M NaCl and 0.2 M Mg2+ by timed high-performance liquid chromatography (HPLC) analysis, exhibits a second-order dependence on 2-MeImpdG concentration, [G]0, indicating a bimolecular mechanism of dimerization in the range 0.02 M ≤ [G]0 ≤ 0.09 M. In the presence of polycytidylate, poly(C), G2p synthesis is accelerated and oligodeoxyguanylate products are formed by incorporation of 2-MeImpdG molecules. The kinetics of G2p formation as a function of both monomer and polymer concentration, expressed in C equivalents, were also determined under the above conditions and exhibited a complex behavior. Specifically, at a constant [poly(C)], values of d[G2p]/dt typically increased with [G]0 with a parabolic upward curvature. At a constant [G]0, values of d[G2p]/dt increase with [poly(C)], but level off at the higher poly(C) concentrations. As [G]0 increases this saturation occurs at a higher poly(C) concentration, a result opposite to expectation for a simple complexation of two reacting monomers with the catalyst prior to reaction. Nevertheless, these results are shown to be quantitatively consistent with a template-directed (TD) mechanism of dimerization where poly(C) acts as the template to bind 2-MeImpdG in a cooperative manner and lead, for the first time, to the formulation of principles that govern template-directed chemistry. Analysis of the kinetic data via a proposed TD cooperative model provides association constants for the affinity between polymer and monomer and the intrinsic reactivity of 2-MeImpdG toward pyrophosphate synthesis. To the best of our knowledge, poly(C)/2-MeImpdG is the first system that could serve as a textbook example of a TD reaction under conditions such that the template is fully saturated by monomers and under conditions that it is not.

Solution structure, mutagenesis, and NH exchange studies of the MutT enzyme-Mg2+-8-oxo-dGMP complex

Massiah,Saraswat,Azurmendi,Mildvan

, p. 247 - 254 (2004)

The MutT pyrophosphohydrolase from E. coli (129 residues) catalyzes the hydrolysis of nucleoside triphosphates (NTP), including 8-oxo-dGTP, by substitution at Pβ, to yield NMP and pyrophosphate. The product, 8-oxo-dGMP is an unusually tight binding, slowly exchanging inhibitor with a K D=52nM, (ΔG°=-9.8kcal/mol) which is 6.1kcal/mol tighter than the binding of dGMP (ΔG°=-3.7kcal/mol). The higher affinity for 8-oxo-dGMP results from a more favorable ΔHbinding (-32kcal/mol) despite an unfavorable -TΔS°binding (+22kcal/mol). The solution structure of the MutT-Mg2+-8-oxo-dGMP complex shows a narrowed, hydrophobic nucleotide-binding cleft with Asn-119 and Arg-78 among the few polar residues. The N119A, N119D, R78K and R78A single mutations, and the R78K+N119A double mutant all showed largely intact active sites, on the basis of small changes in the kinetic parameters of dGTP hydrolysis and in 1H-15N HSQC spectra. However, the N119A mutation profoundly weakened the active site binding of 8-oxo-dGMP by 4.3kcal/mol (1650-fold). The N119D mutation also weakened 8-oxo-dGMP binding but only by 2.1kcal/mol (37-fold), suggesting that Asn-119 functioned both as a hydrogen bond donor to C8O, and a hydrogen bond acceptor from N7H of 8-oxo-dGMP, while aspartate at position -119 functioned as an acceptor of a single hydrogen bond. Much smaller weakening effects (0.3-0.4kcal/mol) on the binding of dGMP and dAMP were found, indicating specific hydrogen bonding of Asn-119 to 8-oxo-dGMP. While formation of the wild type MutT-Mg2+-8-oxo-dGMP complex slowed the backbone NH exchange rates of 45 residues distributed throughout the protein, the same complex of the N119A mutant slowed the exchange rates of only 11 residues at or near the active site, indicating an increase in conformational flexibility of the N119A mutant. The R78K and R78A mutations weakened the binding of 8-oxo-dGMP by 1.7 and 1.1kcal/mol, respectively, indicating a lesser role of Arg-78 than of Asn-119 in the selective binding of 8-oxo-dGMP, likely donating a single hydrogen bond to its C6O. The R78K+N119A double mutant weakened the binding of 8-oxo-dGMP (KI slope=3.1mM) by 6.5±0.2kcal/mol which overlaps, within error with the sum of the effects of the two single mutants (6.0±0.3kcal/mol). Such additive effects of the two single mutants in the double mutant are most simply explained by the independent functioning of Asn-119 and Arg-78 in the binding of 8-oxo-dGMP. Independent functioning of these two residues in nucleotide binding is consistent with their locations in the MutT-Mg 2+-8-oxo-dGMP complex, on opposite sides of the active site cleft, with a distance of 8.4±0.5A? between their side chain nitrogens.

Strand breakage of a (6-4) photoproduct-containing DNA at neutral pH and its repair by the ERCC1-XPF protein complex

Arichi, Norihito,Yamamoto, Junpei,Takahata, Chiaki,Sano, Emi,Masuda, Yuji,Kuraoka, Isao,Iwai, Shigenori

, p. 3526 - 3534 (2013)

The (6-4) photoproduct is one of the major UV-induced lesions in DNA. We previously showed that hydrolytic ring opening of the 5′ base and subsequent hydrolysis of the glycosidic bond of the 3′ component occurred when this photoproduct was treated with aqueous NaOH. In this study, we found that another product was obtained when the (6-4) photoproduct was heated at 90 °C for 6 h, in a 0.1 M solution of N,N′-dimethyl-1,2-ethanediamine adjusted to pH 7.4 with acetic acid. An analysis of the chemical structure of this product revealed that the 5′ base was intact, whereas the glycosidic bond at the 3′ component was hydrolyzed in the same manner. The strand break was detected for a 30-mer oligonucleotide containing the (6-4) photoproduct upon treatment with the above solution or other pH 7.4 solutions containing biogenic amines, such as spermidine and spermine. In the case of spermidine, the rate constant was calculated to be 1.4 × 10-8 s-1 at 37 °C. The strand break occurred even when the oligonucleotide was heated at 90 °C in 0.1 M sodium phosphate (pH 7.0), although this treatment produced several types of 5′ fragments. The Dewar valence isomer was inert to this reaction. The product obtained from the (6-4) photoproduct-containing 30-mer was used to investigate the enzymatic processing of the 3′ end bearing the damaged base and a phosphate. The ERCC1-XPF complex removed several nucleotides containing the damaged base, in the presence of replication protein A. The Royal Society of Chemistry.

Cytotoxicity of guanine-based degradation products contributes to the antiproliferative activity of guanine-rich oligonucleotides

Zhang, Nan,Bing, Tao,Liu, Xiangjun,Qi, Cui,Shen, Luyao,Wang, Linlin,Shangguan, Dihua

, p. 3831 - 3838 (2015/06/25)

Guanine-rich oligonucleotides (GROs) have attracted considerable attention as anticancer agents, because they exhibit cancer-selective antiproliferative activity and can form G-quadruplex structures with higher nuclease resistance and cellular uptake. Recently, a GRO, AS1411 has reached phase II clinical trials for acute myeloid leukemia and renal cell carcinoma. The antiproliferative activity of GROs has been associated with various protein targets; however the real mechanisms of action remain unclear. In this study, we showed evidence that antiproliferative activity of GROs (including AS1411) is mainly contributed by the cytotoxicity of their guanine-based degradation products, such as monophosphate deoxyguanosine (dGMP), deoxyguanosine (dG) and guanine. The GROs with lower nuclease resistance exhibited higher antiproliferative activity. Among nucleotides, nucleosides and nucleobases, only guanine-based compounds showed highly concentration-dependent cytotoxicity. Our results suggest that it is necessary to reconsider the cancer-selective antiproliferative activity of GROs. Since guanine-based compounds are endogenous substances in living organisms, systematic studies of the cytotoxicity of these compounds will provide new information for the understanding of certain diseases and offer useful information for drug design.

Fully automated continuous meso-flow synthesis of 5′-nucleotides and deoxynucleotides

Zhu, Chenjie,Tang, Chenglun,Cao, Zhi,He, Wei,Chen, Yong,Chen, Xiaochun,Guo, Kai,Ying, Hanjie

, p. 1575 - 1581 (2015/02/19)

The first continuous meso-flow synthesis of natural and non-natural 5′-nucleotides and deoxynucleotides is described, representing a significant advance over the corresponding in-flask method. By means of this meso-flow technique, a synthesis with time consumption and high-energy consumption becomes facile to generate products with great efficiency. An abbreviated duration, satisfactory output, and mild reaction conditions are expected to be realized under the present procedure.

Immobilized Drosophila melanogaster deoxyribonucleoside kinase (DmdNK) as a high performing biocatalyst for the synthesis of purine arabinonucleotides

Serra, Immacolata,Conti, Silvia,Piskur, Jure,Clausen, Anders R.,Munch-Petersen, Birgitte,Terreni, Marco,Ubiali, Daniela

, p. 563 - 570 (2014/05/20)

Fruit fly (Drosophila melanogaster) deoxyribonucleoside kinase (DmdNK; EC: 2.7.1.145) was characterized for its substrate specificity towards natural and non-natural nucleosides, confirming its potential in the enzymatic synthesis of modified nucleotides. DmdNK was adsorbed on a solid ion exchange support (bearing primary amino groups) achieving an expressed activity >98%. Upon cross-linking with aldehyde dextran, expressed activity was 30-40%. Both biocatalysts (adsorbed or cross-linked) were stable at pH 10 and room temperature for 24 h (about 70% of retained activity). The cross-linked DmdNK preparation was used for the preparative synthesis of arabinosyladenine monophosphate (araA-MP) and fludarabine monophosphate (FaraAMP). Upon optimization of the reaction conditions (50 mM ammonium acetate, substrate/ATP ratio= 1:1.25, 2 mM MgCl2, 378C, pH 8) immobilized DmdNK afforded the title nucleotides with high conversion (>90%), whereas with the soluble enzyme lower conversions were achieved (78-87%). Arabinosyladenine monophosphate was isolated in 95% yield and high purity (96.5%).

Mechanism of the alkali degradation of (6-4) photoproduct-containing DNA

Arichi, Norihito,Inase, Aki,Eto, Sachise,Mizukoshi, Toshimi,Yamamoto, Junpei,Iwai, Shigenori

, p. 2318 - 2325 (2012/04/10)

The (6-4) photoproduct is one of the major damaged bases produced by ultraviolet light in DNA. This lesion is known to be alkali-labile, and strand breaks occur at its sites when UV-irradiated DNA is treated with hot alkali. We have analyzed the product obtained by the alkali treatment of a dinucleoside monophosphate containing the (6-4) photoproduct, by HPLC, NMR spectroscopy, and mass spectrometry. We previously found that the N3-C4 bond of the 5′ component was hydrolyzed by a mild alkali treatment, and the present study revealed that the following reaction was the hydrolysis of the glycosidic bond at the 3′ component. The sugar moiety of this component was lost, even when a 3′-flanking nucleotide was not present. Glycosidic bond hydrolysis was also observed for a dimer and a trimer containing 5-methyl-2-pyrimidinone, which was used as an analog of the 3′ component of the (6-4) photoproduct, and its mechanism was elucidated. Finally, the alkali treatment of a tetramer, d(GT(6-4)TC), yielded 2′-deoxycytidine 5′-monophosphate, while 2′-deoxyguanosine 3′-monophosphate was not detected. This result demonstrated the hydrolysis of the glycosidic bond at the 3′ component of the (6-4) photoproduct and the subsequent strand break by β-elimination. It was also shown that the glycosidic bond at the 3′ component of the Dewar valence isomer was more alkali-labile than that of the (6-4) photoproduct. The Royal Society of Chemistry 2012.

Two thymidine kinases and one multisubstrate deoxyribonucleoside kinase salvage DNA precursors in Arabidopsis thaliana

Clausen, Anders R.,Girandon, Lenart,Ali, Ashfaq,Knecht, Wolfgang,Rozpedowska, Elzbieta,Sandrini, Michael P. B.,Andreasson, Erik,Munch-Petersen, Birgitte,Piskur, Jure

, p. 3889 - 3897 (2013/01/13)

Deoxyribonucleotides are the building blocks of DNA and can be synthesized via de novo and salvage pathways. Deoxyribonucleoside kinases (EC 2.7.1.145) salvage deoxyribonucleosides by transfer of a phosphate group to the 5' of a deoxyribonucleoside. This salvage pathway is well characterized in mammals, but in contrast, little is known about how plants salvage deoxyribonucleosides. We show that during salvage, deoxyribonucleosides can be phosphorylated by extracts of Arabidopsis thaliana into corresponding monophosphate compounds with an unexpected preference for purines over pyrimidines. Deoxyribonucleoside kinase activities were present in all tissues during all growth stages. In the A. thaliana genome, we identified two types of genes that could encode enzymes which are involved in the salvage of deoxyribonucleosides. Thymidine kinase activity was encoded by two thymidine kinase 1 (EC 2.7.1.21)-like genes (AtTK1a and AtTK1b). Deoxyadenosine, deoxyguanosine and deoxycytidine kinase activities were encoded by a single AtdNK gene. T-DNA insertion lines of AtTK1a and AtTK1b mutant genes had normal growth, although AtTK1a AtTK1b double mutants died at an early stage, which indicates that AtTK1a and AtTK1b catalyze redundant reactions. The results obtained in the present study suggest a crucial role for the salvage of thymidine during early plant development. 2012 The Authors Journal compilation

A single nuclease-resistant linkage in DNA as a versatile tool for the characterization of DNA lesions: Application to the guanine oxidative lesion g+34 generated by metalloporphyrin/KHSO5 reagent

Tomaszewska, Agnieszka,Mourgues, Sophie,Guga, Piotr,Nawrot, Barbara,Pratviel, Genevieve

, p. 2505 - 2512 (2013/01/15)

The oxidation of an oligonucleotide containing a single nuclease-resistant phosphodiester link, a stereoisomerically pure methylphosphonate, by manganese (Mn-TMPyP) or iron (Fe-TMPyP) porphyrin associated to KHSO5 allowed the isolation and characterization of a guanine lesion corresponding to an increase of mass of 34 amu as compared to guanine ( G+34 ), namely, 5-carboxamido-5-formamido-2-iminohydantoin. Enzymatic digestion of the damaged oligonucleotide afforded, apart from the undamaged nucleotide monomer pool, a unique dinucleotide doubly modified with a methylphosphonate and an oxidized guanine base that is suitable for NMR analysis. The method can be applied to the study of any DNA lesion. More importantly, the method can be extended to the analysis of DNA damage in a sequence context. Any preselected residue in a DNA sequence may be individually analyzed by the easy introduction of a single nuclease-resistant link at the 3′- or 5′-position.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 902-04-5